Product logins

Find logins to all Clarivate products below.


The TreatmentTrends: Psoriasis 2015 (US) report explores treatment dynamics and their evolution among 100 U.S. dermatologists, through comprehensive primary research methods. The use of biologic products and Otezla prescribed for psoriasis is covered in particular detail. The report explores dermatologists’ awareness, trial, and usage of currently available brands, as well as familiarity with and interest in key emerging therapies.

Related Market Assessment Reports

Report
Psoriasis | Access and Reimbursement | EU | 2019
MARKET OUTLOOK The treatment landscape for psoriasis in the top 5 European markets (France, Germany, Italy, Spain, UK) is extremely dynamic. Humira (AbbVie), Enbrel (Amgen), Stelara (Janssen),…
Report
Migraine | Special Topics | Spotlight on New Treatments in Migraine (US) | 2021
Since 2018, seven novel drugs have entered the U.S. market for the acute or preventive treatment of migraine, and at least four more are on the short-term horizon. Understanding how prescribers…
Report
Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)
Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant…
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…